Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of Tumor Necrosis Factor and Interleukin-10 Analysis in the Follow-up of Nonalcoholic Fatty Liver Disease Progression

  • Research Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Tumor necrosis factor (TNF-α) is a cytokine involved in systemic inflammation during acute phase reactions. The current study was designed to investigate the levels of pro-inflammatory cytokine (TNF-α) along with the anti-inflammatory cytokine (IL-10) during progression of non-alcoholic fatty liver disease (NAFLD) from simple steatosis to non-alcoholic steatohepatitis (NASH) and fibrosis in diabetic patients, and correlate the levels of cytokines with the progression of NAFLD. Fifty-two diabetic patients compared to 18 healthy controls were participated in this study. Based on clinical diagnosis, patients were divided into three groups: simple steatosis, NASH and fibrosis. Serum liver function tests, fasting blood glucose, bilirubin, ALT, AST, TNF-α, IL-10 and lipid profile were measured. TNF-α levels were significantly higher in NAFLD patients compared to control subjects with a significant positive correlation with body mass index and fasting blood glucose (FBG) but with negative correlation with IL-10. Serum IL-10 levels were significantly lower in NAFLD patients compared with controls. A positive correlation between IL-10 and HDL-C with concomitant negative correlation between IL-10 and FBG and triacylglycerides was found. Cytokine analyses showed that there was a prominent imbalance between TNF-α and IL-10 in patients with NAFLD, and this imbalance increase by increasing the progression of NAFLD especially in obese diabetic patients. TNF-α and IL-10 could be used in diagnosis and follow-up of NAFLD stages in a way to avoid liver biopsies in greater proportion of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56:1145–51.

    Article  PubMed  Google Scholar 

  2. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.

    Article  PubMed  Google Scholar 

  3. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711–25.

    Article  PubMed  CAS  Google Scholar 

  4. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048–58.

    Article  PubMed  Google Scholar 

  5. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114:842–5.

    Article  PubMed  CAS  Google Scholar 

  6. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med. 2008;29:9–16.

    Article  PubMed  CAS  Google Scholar 

  7. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta. 2011;412:1297–305.

    Article  PubMed  CAS  Google Scholar 

  8. Wong VW, Chan HL, Hui AY, Chan KF, Liew CT, Chan FK, Sung JJ. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol Ther. 2004;20(1):45–9.

    Article  PubMed  Google Scholar 

  9. Angulo P. Non alcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.

    Article  PubMed  CAS  Google Scholar 

  10. Vanni E, Bugianesia E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42:320–30.

    Article  PubMed  CAS  Google Scholar 

  11. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52:59–69.

    Article  PubMed  CAS  Google Scholar 

  12. Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, Qin L, Szabo G, Wheeler M, Zou J. Cytokines and alcohol. Alcohol Clin Exp Res. 2006;30:720–30.

    Article  PubMed  CAS  Google Scholar 

  13. Cameron RG, Neuman MG. Novel morphologic findings in alcoholic liver disease. Clin Biochem. 1999;32(7):579–84.

    Article  PubMed  CAS  Google Scholar 

  14. Das SK, Balakrishnan V. Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease. Ind J Clin Biochem. 2011;26(2):202–9.

    Article  CAS  Google Scholar 

  15. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):179–85.

    Article  PubMed  Google Scholar 

  16. Mottin CC, Moretto M, Padoin AV. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg. 2004;14:635–7.

    Article  PubMed  Google Scholar 

  17. Freidewald WT, Levy RJ, Fredrickson DS. Estimation of concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.

    Google Scholar 

  18. Stepaniak J, Shuster J, Sundick R. Production and determination of recombinant human cytokines. J Cytokine Res. 1995;19:515–26.

    Article  Google Scholar 

  19. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment cytokines in NAFLD. Am J Gastroenterol. 2008;103:1036–42.

    Article  PubMed  CAS  Google Scholar 

  20. Lu H, Zeng L, Liang B, Shu X, Xie D. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res. 2009;40:571–5.

    Article  PubMed  CAS  Google Scholar 

  21. Edens M, Kuipers F, Stolk R. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev. 2009;10:412–9.

    Article  PubMed  CAS  Google Scholar 

  22. Collier J. Non-alcoholic fatty liver disease. Medicine. 2007;35(2):86–8.

    Article  Google Scholar 

  23. Giorgio R, Wolfgang K, Joseph S, Klaus P. Non-alcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging. Acta Pediatr. 2006;95(7):833–7.

    Article  Google Scholar 

  24. Steve C, Anna M. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2005;21(6):702–7.

    Article  Google Scholar 

  25. Riley TR, Taheri M, Schreibman IR. Does weight history affect fibrosis in the setting of chronic liver disease? J Gastrointest Liver Dis. 2009;18(3):299–302.

    Google Scholar 

  26. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Non-alcoholic fatty liver and insulin resistance: a cause–effect relationship? Dig Liver Dis. 2004;36(3):165–73.

    Article  PubMed  CAS  Google Scholar 

  27. Uchil D, Pipalia D, Chawla M, Patel R, Maniar S, Narayani, Juneja A. Non-alcoholic fatty liver disease (NAFLD)—The hepatic component of metabolic syndrome. J Assoc Physicians India. 2009;57:201–4.

    PubMed  Google Scholar 

  28. Simonen P, Kotronen A, Hallikainen M, Sevastianova K, Makkonen J, Hakkarainen A, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol. 2011;54:153–9.

    Article  PubMed  CAS  Google Scholar 

  29. Nobili V, Alisi A, Vania A, Tiribelli C, Pietrobattista A, Bedogni G. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med. 2009;7(21).

  30. Mouralidarane A, Oben JA, Soeda J. Pathophysiology and clinical management of nonalcoholic fatty liver disease. Medicine. 2011;39(10):592–6.

    Article  Google Scholar 

  31. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem. 1996;271(22):13018–22.

    Article  PubMed  CAS  Google Scholar 

  32. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343:1467–76.

    Article  PubMed  CAS  Google Scholar 

  33. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol. 2008;14(2):193–9.

    Article  PubMed  CAS  Google Scholar 

  34. Zhang L, Wang XZ. Interleukin-10 and chronic liver disease. World J Gastroenterol. 2006;12(11):1681–5.

    PubMed  CAS  Google Scholar 

  35. Straczkowski M, Kowalska I, Nikolajuk A, Krukowska A, Gorska M. Plasma interleukin-10 concentration is positively related to insulin sensitivity in young healthy individuals. Diabetes Care. 2005;28(8):2036–7.

    Article  PubMed  CAS  Google Scholar 

  36. Uysal S, Armutcu F, Aydogan T, Akin K, Ikizek M, Yigitoglu MR. Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis. Clin Biochem. 2011;44(17–18):1375–9.

    Article  PubMed  CAS  Google Scholar 

  37. Angulo P. Treatment of non alcoholic fatty liver disease. Ann Hepatol. 2002;1(1):12–9.

    PubMed  Google Scholar 

  38. Cintra DE, Pauli JR, Araújo EP, Moraes JC, De Souza CT, Milanski M, et al. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol. 2008;48(4):628–37.

    Article  PubMed  CAS  Google Scholar 

  39. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 2012;18(8):727–35.

    Article  PubMed  CAS  Google Scholar 

  40. Hashem RM, Mahmoud MF, El-Moselhy MA, Soliman HM. Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis. Eur J Gastroenterol Hepatol. 2008;20(10):995–1001.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt

    Walid E. Zahran, Kholoud A. Salah El-Dien & Philip G. Kamel

  2. Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Ahmed Shawky El-Sawaby

Authors
  1. Walid E. Zahran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kholoud A. Salah El-Dien
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip G. Kamel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmed Shawky El-Sawaby
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Walid E. Zahran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zahran, W.E., Salah El-Dien, K.A., Kamel, P.G. et al. Efficacy of Tumor Necrosis Factor and Interleukin-10 Analysis in the Follow-up of Nonalcoholic Fatty Liver Disease Progression. Ind J Clin Biochem 28, 141–146 (2013). https://doi.org/10.1007/s12291-012-0236-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-012-0236-5

Keywords

Search

Navigation